New drug target for X-linked lymphoproliferative disease identified

January 13, 2016, St. Jude Children's Research Hospital

An international team of scientists including researchers at St. Jude Children's Research Hospital have identified a crucial signaling enzyme as a possible therapeutic target for the treatment of a heritable immune disease. X-linked lymphoproliferative disease is a life-threatening condition that has few treatment options. Affected individuals are vulnerable to massive accumulation and activation of white blood cells known as T cells should they become infected with Epstein-Barr virus, the virus that causes infectious mononucleosis. Without treatment, this accumulation of activated T cells leads to severe organ damage and, in many cases, death. The study appears online in the January 13 issue of Science Translational Medicine.

Scientists have known for some time that X-linked lymphoproliferative is a heritable disorder caused by germline mutations in the SH2D1A gene. When this gene is affected it leads to defects in a specific adaptor molecule known as SAP (Signaling Lymphocytic Activation Molecule-associated protein) that plays important roles in the signaling events related to receptors on the surface of T . Without an effective SAP adaptor molecule, normal cell death processes (apoptosis) are impaired and an enzyme known as diacylglycerol kinase alpha is activated. This team questioned whether the over-activation of diacylglycerol kinase alpha might contribute to the reduced apoptosis of X-linked lymphoproliferative disease T cells and the accumulation of T cells that occurs following infection with Epstein-Barr virus.

The researchers showed that inhibition of diacylglycerol kinase alpha using specific drugs restored the sensitivity of X-linked lymphoproliferative T cells to cell death. The scientists observed similar results when they looked at the effects of "knocking out" the same enzyme in cultured X-linked lymphoproliferative T cells using inhibitory RNA molecules. Consistent with these observations, pharmacologic inhibition of diacylglycerol kinase alpha also curtailed the expansion of T cells in virus-infected mice that serve as a model organism to study X-linked lymphoproliferative disease.

"Patients with X-linked lymphoproliferative disease are prone to severe Epstein-Barr due to a weakened immune system," said Kim Nichols, a member of the St. Jude Department of Oncology and one of the lead authors of the study. Dr. Nichols identified the SH2D1A gene in 1998 and her laboratory has been studying how SAP regulates immune cell development and function for over 15 years. "Infection with Epstein-Barr virus can have potentially fatal consequences for these patients." She added: "This severe disease is a double-edged sword. On the one hand the immune system is significantly weakened. However, detrimental side effects occur due to the expansion and hyper-activation of T cells. Together with our collaborators in Europe and other institutions in the United States, we wanted to establish the biochemical mechanism underlying these changes so that we could develop better treatments for X-linked lymphoproliferative disease patients experiencing hyper-inflammation."

"Our findings suggest that inhibition of diacylglycerol kinase alpha could reverse some of the life-threatening effects linked to Epstein-Barr virus infection of patients with X-linked lymphoproliferative disease," said Nichols.

T cells from patients with X-linked lymphoproliferative disease are hard to obtain in sufficient quantities to permit many experiments and such experiments in the laboratory do not fully recapitulate the manifestations that are seen in patients. The St. Jude researchers therefore turned to a model system that replicates the conditions of the disease in genetically modified mice. Mice deficient in SAP, when challenged with lymphocytic choriomeningitis virus, show similar symptoms to patients with X-linked lymphoproliferative disease, including an abnormal accumulation and activation of T cells. Collectively the data from cultured human T cells and SAP-deficient mice show that inhibition of diacylglycerol kinase alpha had beneficial effects on restoring the natural balance of the immune system.

"These results are very exciting and provide proof of principle that treatment with an inhibitor of diacylglycerol kinase alpha could help patients with the symptoms experienced after Epstein-Barr virus infection. However, this work is still at an early preclinical stage of investigation. We have identified a new target for X-linked lymphoproliferative disease but further work is needed to identify and advance the best drug candidate from preclinical testing to a viable treatment option for patients."

Explore further: Engineered cells could help tackle the third most common cancer in Chinese males

More information: "Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1," DOI: 10.1126/scitranslmed.aad1565

Related Stories

Engineered cells could help tackle the third most common cancer in Chinese males

March 10, 2015
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

Is the detection of early markers of Epstein Barr virus of diagnostic value?

November 16, 2012
Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and a risk for serious disease in liver transplant recipients. Molecular tests that can identify early protein markers produced by EBV may have value for diagnosing ...

Young killer cells protect against infectious mononucleosis

December 19, 2013
More than 90 percent of all adults are carriers of the oncogenic Epstein-Barr Virus (EBV). Primary infection with this herpes virus as a young child is generally not linked to any symptoms, and usually offers life-long protection ...

Study: Epstein Barr virus protects against autoimmune disease

April 2, 2012
To the surprise of investigating researchers, an animal model of Epstein Barr virus protected lupus-prone mice against development of the autoimmune disease. Earlier work had suggested that EBV might promote the development ...

Researchers elucidate a molecular mechanism associated with an immune disorder

June 7, 2012
A team of researchers at the IRCM led by Dr. André Veillette made an important breakthrough in the field of immunology, which will be published online today by the scientific journal Immunity. The scientists explained ...

Recommended for you

Bioengineered soft microfibers improve T-cell production

January 18, 2018
T cells play a key role in the body's immune response against pathogens. As a new class of therapeutic approaches, T cells are being harnessed to fight cancer, promising more precise, longer-lasting mitigation than traditional, ...

Weight flux alters molecular profile, study finds

January 17, 2018
The human body undergoes dramatic changes during even short periods of weight gain and loss, according to a study led by researchers at the Stanford University School of Medicine.

Secrets of longevity protein revealed in new study

January 17, 2018
Named after the Greek goddess who spun the thread of life, Klotho proteins play an important role in the regulation of longevity and metabolism. In a recent Yale-led study, researchers revealed the three-dimensional structure ...

The HLF gene protects blood stem cells by maintaining them in a resting state

January 17, 2018
The HLF gene is necessary for maintaining blood stem cells in a resting state, which is crucial for ensuring normal blood production. This has been shown by a new research study from Lund University in Sweden published in ...

Magnetically applied MicroRNAs could one day help relieve constipation

January 17, 2018
Constipation is an underestimated and debilitating medical issue related to the opioid epidemic. As a growing concern, researchers look to new tools to help patients with this side effect of opioid use and aging.

Researchers devise decoy molecule to block pain where it starts

January 16, 2018
For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he's developing new ways to blunt pain.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.